Details
| Originalsprache | Englisch |
|---|---|
| Seiten (von - bis) | 451-464 |
| Seitenumfang | 14 |
| Fachzeitschrift | European Journal of Health Economics |
| Jahrgang | 21 |
| Ausgabenummer | 3 |
| Frühes Online-Datum | 2 Jan. 2020 |
| Publikationsstatus | Veröffentlicht - Apr. 2020 |
Abstract
Purpose: This study estimates the healthcare costs associated with breast cancer (BC) for different treatment phases (initial, intermediate, terminal) in Germany from the payer’s perspective. Methods: The analysis uses claims data from the AOK Bayern covering 2011–2014 for continuously insured BC patients identified through inpatient and outpatient diagnoses. We calculate the healthcare costs attributable to BC using a control group design comparing the target population to a 1:2 matched control group adjusted for age, gender, and comorbidities. For incident and prevalent BC cases, we calculate age-standardized phase-specific incremental costs stratified by cost domain. Results: The initial, intermediate, and terminal phases comprise 3841, 28,315, and 1767 BC cases, respectively. BC-related incremental costs follow a u-shaped curve, with costs highest near diagnosis and death, and lower in between. With average costs of €33,237 per incident and €28,211 per prevalent case in the remaining 11 months before death, the highest BC-related incremental healthcare costs can be found in the terminal phase. In the initial phase, there were mean incremental costs of €21,455 the first 11 months after diagnosis. In the intermediate phase, incremental costs totaled €2851 per incident and €2387 per prevalent case per year. Healthcare costs decreased with age in most phases. The cost drivers depend on the treatment phase, with cytostatic drugs and inpatient treatment showing the highest economic impact in most phases. Conclusion: The study concludes that BC care costs impose a relevant economic burden on statutory health insurance and vary substantially depending on the treatment phase.
ASJC Scopus Sachgebiete
- Volkswirtschaftslehre, Ökonometrie und Finanzen (insg.)
- Volkswirtschaftslehre, Ökonometrie und Finanzen (sonstige)
- Medizin (insg.)
- Health policy
Ziele für nachhaltige Entwicklung
Zitieren
- Standard
- Harvard
- Apa
- Vancouver
- BibTex
- RIS
in: European Journal of Health Economics, Jahrgang 21, Nr. 3, 04.2020, S. 451-464.
Publikation: Beitrag in Fachzeitschrift › Artikel › Forschung › Peer-Review
}
TY - JOUR
T1 - Healthcare costs associated with breast cancer in Germany
T2 - a claims data analysis
AU - Kreis, Kristine
AU - Plöthner, Marika
AU - Schmidt, Torben
AU - Seufert, Richard
AU - Schreeb, Katharina
AU - Jahndel, Veronika
AU - Maas, Sylke
AU - Kuhlmann, Alexander
AU - Zeidler, Jan
AU - Schramm, Anja
N1 - Funding information: This study was supported by the Federal Ministry of Education and Research (Grant number 13GW0078B).
PY - 2020/4
Y1 - 2020/4
N2 - Purpose: This study estimates the healthcare costs associated with breast cancer (BC) for different treatment phases (initial, intermediate, terminal) in Germany from the payer’s perspective. Methods: The analysis uses claims data from the AOK Bayern covering 2011–2014 for continuously insured BC patients identified through inpatient and outpatient diagnoses. We calculate the healthcare costs attributable to BC using a control group design comparing the target population to a 1:2 matched control group adjusted for age, gender, and comorbidities. For incident and prevalent BC cases, we calculate age-standardized phase-specific incremental costs stratified by cost domain. Results: The initial, intermediate, and terminal phases comprise 3841, 28,315, and 1767 BC cases, respectively. BC-related incremental costs follow a u-shaped curve, with costs highest near diagnosis and death, and lower in between. With average costs of €33,237 per incident and €28,211 per prevalent case in the remaining 11 months before death, the highest BC-related incremental healthcare costs can be found in the terminal phase. In the initial phase, there were mean incremental costs of €21,455 the first 11 months after diagnosis. In the intermediate phase, incremental costs totaled €2851 per incident and €2387 per prevalent case per year. Healthcare costs decreased with age in most phases. The cost drivers depend on the treatment phase, with cytostatic drugs and inpatient treatment showing the highest economic impact in most phases. Conclusion: The study concludes that BC care costs impose a relevant economic burden on statutory health insurance and vary substantially depending on the treatment phase.
AB - Purpose: This study estimates the healthcare costs associated with breast cancer (BC) for different treatment phases (initial, intermediate, terminal) in Germany from the payer’s perspective. Methods: The analysis uses claims data from the AOK Bayern covering 2011–2014 for continuously insured BC patients identified through inpatient and outpatient diagnoses. We calculate the healthcare costs attributable to BC using a control group design comparing the target population to a 1:2 matched control group adjusted for age, gender, and comorbidities. For incident and prevalent BC cases, we calculate age-standardized phase-specific incremental costs stratified by cost domain. Results: The initial, intermediate, and terminal phases comprise 3841, 28,315, and 1767 BC cases, respectively. BC-related incremental costs follow a u-shaped curve, with costs highest near diagnosis and death, and lower in between. With average costs of €33,237 per incident and €28,211 per prevalent case in the remaining 11 months before death, the highest BC-related incremental healthcare costs can be found in the terminal phase. In the initial phase, there were mean incremental costs of €21,455 the first 11 months after diagnosis. In the intermediate phase, incremental costs totaled €2851 per incident and €2387 per prevalent case per year. Healthcare costs decreased with age in most phases. The cost drivers depend on the treatment phase, with cytostatic drugs and inpatient treatment showing the highest economic impact in most phases. Conclusion: The study concludes that BC care costs impose a relevant economic burden on statutory health insurance and vary substantially depending on the treatment phase.
KW - Breast cancer
KW - Claims data
KW - Disease cost
KW - Germany
KW - Joinpoint
UR - http://www.scopus.com/inward/record.url?scp=85077576721&partnerID=8YFLogxK
U2 - 10.1007/s10198-019-01148-w
DO - 10.1007/s10198-019-01148-w
M3 - Article
C2 - 31897812
AN - SCOPUS:85077576721
VL - 21
SP - 451
EP - 464
JO - European Journal of Health Economics
JF - European Journal of Health Economics
SN - 1618-7598
IS - 3
ER -